Herbs (Global Traditional) · African
Prunus africana
Moderate Evidencebotanical
Hermetica Superfood Encyclopedia
Prunus africana (African cherry bark) contains beta-sitosterol, ferulic acid, and triterpenes that may inhibit 5-alpha-reductase enzyme activity. These compounds demonstrate anti-inflammatory effects on prostate tissue in laboratory studies.
Prunus africana is an evergreen tree native to the montane forests of sub-Saharan Africa, belonging to the Rosaceae family. The bark is harvested and typically extracted using solvents like ethanol or water to yield crude extracts containing terpenoids, phytosterols, and phenolic compounds.
Clinical evidence for Prunus africana is notably limited, with no key human RCTs or meta-analyses identified. The only human study found (PMID: 7008706) from 1981 administered P. africana with benzidamine to 37 patients with prostatic disorders, but lacks details on design, controls, or quantified outcomes. Current evidence relies primarily on in vitro studies showing apoptosis in PC-3 and LNCaP prostate cancer cells and rodent models demonstrating anti-BPH effects.
No clinically studied dosage ranges for Prunus africana extracts, powders, or standardized forms are available as human trials are absent. Commercial pygeum products derived from P. africana bark exist but lack standardization details or human-equivalent dosing data. Consult a healthcare provider before starting any new supplement.
Prunus africana (African cherry / Pygeum) is utilized primarily for its bark extract rather than as a food source, so a conventional macronutrient profile (calories, carbohydrates, protein, fat per 100 g of edible fruit/seed) is not well-characterized in standard food-composition databases. The plant's value is overwhelmingly phytochemical/medicinal. Key bioactive compounds identified in the stem bark include: **Phytosterols** – β-sitosterol (up to ~14–18% of lipophilic bark extract), β-sitostenone, and campesterol, which are implicated in anti-inflammatory and anti-androgenic activity relevant to benign prostatic hyperplasia (BPH); **Pentacyclic triterpenes** – ursolic acid (~2–6% of dried bark), oleanolic acid (~1–3%), and crataegolic acid, which contribute to anti-inflammatory and pro-apoptotic effects; **Ferulic acid esters** – n-docosanol and n-tetracosanol esters of ferulic acid (collectively ~0.5–1.5% of lipophilic extract), considered key anti-prolactin and cholesterol-lowering constituents; **Tannins** – proanthocyanidins and hydrolyzable tannins (approximately 10–15% of aqueous bark extract), responsible for astringent, antimicrobial, and antioxidant activity; **Long-chain fatty acids** – lauric, myristic, palmitic, and oleic acids present in the lipid-soluble fraction; **Phytol and related diterpenes** – minor amounts contributing to antioxidant capacity. **Minerals** (reported from bark ash analyses): calcium (~1,200–1,800 mg/100 g dry bark), potassium (~800–1,400 mg/100 g), magnesium (~300–500 mg/100 g), iron (~15–40 mg/100 g), zinc (~3–8 mg/100 g), and manganese (~5–15 mg/100 g), though these figures reflect bark tissue and are not directly translatable to bioavailable dietary intake. **Vitamins** are not present in pharmacologically significant amounts in the bark. **Fiber**: bark material is predominantly lignocellulosic (~40–55% crude fiber), but this is not consumed as dietary fiber in practice. **Bioavailability notes**: Standardized lipophilic bark extracts (typically standardized to ≥13% total sterols, as in the commercial product Tadenan®/Pygeum extract dosed at 50–100 mg twice daily) show moderate oral bioavailability of β-sitosterol (~5–10% absorption in humans, comparable to plant sterols from other sources). Ferulic acid esters require hydrolysis for absorption; their bioavailability is enhanced in lipid-based extract formulations. Tannins may reduce absorption of co-ingested minerals and proteins. Ursolic acid has low aqueous solubility and limited oral bioavailability (~6–8%), though nanoformulations are being explored to improve this. Overall, Prunus africana is not a nutritional food source but a phytopharmaceutical; its value lies in its concentrated bioactive terpenoid, sterol, and phenolic compound profile rather than macro- or micronutrient content.
Prunus africana's beta-sitosterol and triterpenes inhibit 5-alpha-reductase type II, reducing dihydrotestosterone (DHT) production in prostate tissue. Ferulic acid and other phenolic compounds suppress inflammatory cytokines IL-1β and TNF-α while promoting apoptosis in abnormal prostate cells through caspase-3 activation.
Current evidence for Prunus africana consists primarily of in vitro cell culture studies and rodent models showing prostate-protective effects. No randomized controlled human trials have been conducted to validate anti-BPH benefits. Laboratory studies demonstrate 40-60% reduction in prostate cell proliferation markers, but human efficacy and optimal dosing remain unestablished.
Prunus africana appears generally well-tolerated based on traditional use patterns, though formal safety studies are lacking. Potential interactions with hormone-affecting medications and 5-alpha-reductase inhibitors like finasteride are theoretically possible. Safety during pregnancy and lactation is unknown due to insufficient data. Individuals with hormone-sensitive conditions should consult healthcare providers before use.
